市场调查报告书
商品编码
1617669
製药的巨量资料 - Strategic IntelligenceStrategic Intelligence: Big Data in Pharma |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
整个製药业正在广泛产生大数据
全球製药领域从各种来源产生大量数据,包括病患登记、临床试验和穿戴式技术。这些资料集如此庞大、复杂且非结构化,传统的大数据分析方法在处理它们时效率低。
因此,製药业正在大数据分析技术方面进行创新,这些技术可以保护、储存、处理、分析、聚合和整合大量复杂的资料集,以产生新的见解。此外,这些技术可以透过机器学习(ML)、人工智慧、物联网、数位孪生等来实现。
本报告提供了全球製药业的研究和分析,包括有关医疗、宏观经济、技术和监管趋势将如何影响製药业大数据的最新见解和预测,我们提供了对关键参与者和未来颠覆者的见解。
Big data is generated extensively across pharma
The international pharmaceutical landscape generates vast amounts of data from a variety of sources, such as patient registries, clinical trials, wearable technologies, and more. Such datasets are extremely vast, complex, and unstructured, rendering traditional big data analytical methodologies inefficient for processing.
As a result, organizations within the pharmaceutical industry are innovating big data analytical technologies that can secure, store, process, analyze, aggregate, and integrate vast and complex datasets for the purpose of acquiring novel insights. Furthermore, these technologies can be implemented with machine learning (ML), artificial intelligence (AI), Internet of Things (IoT), digital twins, and more.
This report consolidates GlobalData's latest thinking and forecasts around how the healthcare, macroeconomic, technology, and regulatory trends will impact the big data in pharma space, as well as providing insights into the leading players and future disruptors across the value chain, and providing insights into key drugs and markets from GlobalData's Pharma Intelligence Center. Additionally, this report is designed to provide strategic planners, competitive intelligence professionals and key stakeholders in the pharmaceutical industry a clear view of the opportunities and risks over the foreseeable future for big data.